|1.||Sabnis, Gauri J: 1 article (01/2008)|
|2.||Macedo, Luciana: 1 article (01/2008)|
|3.||Schayowitz, Adam: 1 article (01/2008)|
|4.||Brodie, Angela: 1 article (01/2008)|
|5.||Goloubeva, Olga: 1 article (01/2008)|
|6.||Zhu, Yue: 1 article (01/2008)|
|7.||Pendergrass, Kelly B: 1 article (11/2007)|
|8.||Langecker, Peter: 1 article (11/2007)|
|9.||Manikhas, Georgiy N: 1 article (11/2007)|
|10.||Bondarenko, Igor N: 1 article (11/2007)|
01/01/1989 - "SH 489 and MDL 18962 did not affect tumor growth. "
01/01/1991 - "Conversely, atamestane, MDL 18962 and oral exemestane did not affect growth of established tumours nor influenced the appearance of new neoplasms. "
01/01/1989 - "The present results clearly demonstrate that, in spite of the counter regulation, a pure aromatase inhibitor such as atamestane in sufficiently high doses is able to inhibit the growth of DMBA-induced mammary tumors in intact female rats."
01/01/1989 - "Antitumor effect of a specific aromatase inhibitor, 1-methyl-androsta-1,4-diene-3,17-dione (atamestane), in female rats bearing DMBA-induced mammary tumors."
01/01/1989 - "In this study, the efficacy of atamestane in suppressing tumor growth was evaluated in comparing with that of a non-steroidal aromatase inhibitor (CGS 16949A, Ciba-Geigy) and ovariectomy. "
|2.||Prostatic Hyperplasia (Benign Prostatic Hyperplasia)
08/01/1995 - "Placebo controlled double-blind study to test the efficacy of the aromatase inhibitor atamestane in patients with benign prostatic hyperplasia not requiring operation. "
03/01/1993 - "Atamestane: an aromatase inhibitor for the treatment of benign prostatic hyperplasia. "
11/01/1991 - "In male volunteers and patients with benign prostatic hyperplasia (BPH), atamestane induces an expected reduction of serum (and BPH tissue) estrogen concentrations without significant changes in androgen levels. "
11/01/1991 - "Atamestane, a new aromatase inhibitor for the management of benign prostatic hyperplasia."
10/01/1996 - "Estrogen reduction by aromatase inhibition for benign prostatic hyperplasia: results of a double-blind, placebo-controlled, randomized clinical trial using two doses of the aromatase-inhibitor atamestane. "
|3.||Breast Neoplasms (Breast Cancer)
01/01/2008 - "In this current study we compared the effect of an AE toremifene and steroidal AI atamestane, alone or in combination, on growth of hormone-dependent human breast cancer. "
11/01/2007 - "Phase III, double-blind, controlled trial of atamestane plus toremifene compared with letrozole in postmenopausal women with advanced receptor-positive breast cancer."
11/01/2007 - "To compare time to progression (TTP) with a steroidal aromatase inhibitor (AI) atamestane (ATA) combined with toremifene (TOR; complete estrogen blockade) versus letrozole (LET) in receptor-positive advanced breast cancer (ABC). "
|4.||Prostatic Neoplasms (Prostate Cancer)
03/01/1993 - "In view of the well established clinical results of the deprivation of androgens through orchiectomy in prostatic cancer and the structural similarities of 4-androsten-3,17-dione and atamestane (1-methyl-ADD), we studied the influence of 1-methyl-ADD on the conversion of 4-androsten-3,17-dione to testosterone by the 17 beta-hydroxysteroid reductase enzyme in human testicular tissue. "
|5.||Chromosome Aberrations (Chromosome Abnormalities)
01/01/1996 - "The cytogenetic potential of 10 sex steroids (cyproterone acetate, drospirenone, gestodene, cyclodiol, cyclotriol, ethinylestradiol, atamestane, lilopristone, onapristone and propylmesterolone) with various medical indications was determined using the chromosomal aberration test in human lymphocytes in vitro and the mouse bone marrow micronucleus test in vivo. "